Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 709 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Decadron Clear all

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: dexamethasone, temsirolimus, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Las Angeles, California

Conditions: Total Knee Replacement, Knee Arthroplasty
Interventions: Bupivacaine-Liposomal Bupivacaine, Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Asparaginase, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Filgrastim, Hydrocortisone Sodium Succinate, Ifosfamide, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisone, Radiation Therapy, Vincristine Sulfate; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 30 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 118
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 94 more

Conditions: Anesthesia, Pediatrics, Surgery
Interventions: regional nerve block, Antiemetic; Procedure · Drug
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 18 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Pain, Chronic Pain
Interventions: Dexamethasone, Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 55 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
Interventions: Acetaminophen, Dexamethasone, Diphenhydramine, Flotetuzumab, Ibuprofen, Ranitidine; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Duarte, California

Conditions: Lymphoma
Interventions: Cyclophosphamide, Mesna, Vincristine, Methotrexate, Ara-C, Dexamethasone, G-CSF, Doxil; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain, Postoperative
Interventions: Local anesthesia at incision site, Sham QL, Sham Local, QL; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Ixazomib, Lenalidomide, Dexamethasone; Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 10
States / cities: Duarte, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: Prostate Cancer
Interventions: dexamethasone, doxorubicin; Drug
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
Interventions: Blinatumomab, Oncaspar, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Mercaptopurine, Methotrexate, Vincristine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 51 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumors
Interventions: Dexamethasone, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2028
U.S. locations: 2
States / cities: Houston, Texas

Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Interventions: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, Venetoclax, Bortezomib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, Thioguanine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 4
States / cities: San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more

Conditions: Analgesic Drug Dependence, Colectomy
Interventions: Opioid Anesthesia, Opioid-free Anesthesia; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent Adult Diffuse Large Cell Lymphoma, Retinal Lymphoma
Interventions: Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more

Conditions: Multiple Myeloma
Interventions: Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Myeloma
Interventions: Clarithromycin, Dexamethasone, Ixazomib Citrate, Pomalidomide; Drug
Lead sponsor: Joseph Tuscano; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 3
States / cities: La Jolla, California • Orange, California • Sacramento, California

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Carfilzomib, Dexamethasone, Nivolumab, Pelareorep; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Salt Lake City, Utah

Conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions: Dexamethasone, Exercise Intervention, Placebo Administration; Drug · Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Selinexor, Liposomal doxorubicin, Dexamethasone; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Tampa, Florida • Detroit, Michigan

Conditions: Mesothelioma
Interventions: LMB-100, ipilimumab, Diphenhydramine, Famotidine, Acetaminophen, Dexamethasone, Biopsy, FDG-PET, CT CAP, MRI, ECG, Echocardiogram; Biological · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcohol Use Disorder
Interventions: Dexamethasone Oral, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Patient Preference, Patient Outcomes, Post-Operative Inflammation, Grade of Post-Operative Cystoid Macular Edema, Rate of Post-Operative Cystoid Macular Edema
Interventions: Dextenza, Topical Prednisolone; Drug
Lead sponsor: Vance Thompson Vision - MT; Other
Eligibility: 22 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Non-Infectious Anterior Uveitis
Interventions: 8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops; Drug
Lead sponsor: Aciont Inc; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more

Search by objective public record fields.

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery

Dexamethasone and Pain Following Total Knee Arthroplasty

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer

ALL Backbone in AYAs

Dexamethasone for Symptom Burden in Advanced Cancer Patients

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Opioid Free Anesthesia vs. Opioid Anesthesia Techniques.

Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Dexamethasone to Target Stress and Immune System Mechanisms Underlying Alcohol Craving

The PRIME Study: A Randomized, Controlled, Prospective Study

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis